RecruitingPhase 1Phase 2NCT07660406

Analyse of Diagnosis Value of Keloid on 68Ga-RGD PET-CT


Sponsor

Peking Union Medical College Hospital

Enrollment

30 participants

Start Date

Aug 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Keloids are often described as benign dermal fibroproliferative lesions characterized by increased growth beyond the boundaries of the original wound margin.Fibroblasts are considered to be the key cellular mediators of fibrogenesis in keloid scars. Thus this prospective study is going to investigate whether 68Ga-RGD PET/CT may provide evidence for diagnosis and evaluate the effectiveness of treatment.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called 68Ga-RGD for people with keloid. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG68Ga-RGD

Intravenous injection of one dosage of 18.5-22.2MBq (0.5-0.6 mCi)/Kg 68Ga-FAPI. Tracer doses of 68Ga- FAPI will be used to image lesions of keloid by PET/ CT.


Locations(1)

Peking Union Medical College Hospital

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07660406


Related Trials